Business
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the
About this update from Opko Health, Inc.
[{"type":"text","content":"ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.\n\n \n \n \n \n \n \n\n \nBioReference announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million patients. GenPath, BioReference's specialty health division, currently offers, ClariTest™ Core, which utilizes the same core technology as the Harmony Prenatal Test. The acquisition of Ariosa will complement this current NIPS offering.\n\"Throughout BioReference's 40 year legacy of diagnostic testing, women's health has been at the forefront of our focus,\" said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. \"Last year, there were about six million pregnancies in the U.S., and prenatal screening for Down syndrome has become common practice. Acquiring the U.S. Ariosa centralized laboratory prenatal testing business allows us to expand our NIPS offerings and further underscores our commitment to prenatal screening, allowing BioReference and GenPath to advance high quality and accessible testing that positively impacts the medical care and outcomes of patients and their families.\"\nFor more information, please visit www.bioreference.com and www.genpath.com. \nAbout BioReference Laboratories, Inc.BioReference Laboratories, Inc., is one of the largest full service specialty laboratories in the United States that gives healthcare providers and patients the power to make confident healthcare decisions. With a focus on genetics, oncology, urology and women's health, BioReference offers comprehensive test solutions and unparalleled expertise based on a 40 year legacy of proven science. The company is in-network with the largest health plans in the United States, serves approximately 19 million patients annually, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 300 M.D., D.O., Ph.D., genetic counselors and other professional clinical and scientific personnel. With a national footprint and niche market expe...